跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 60,400 条关于
“DNAM-1 (CD226)”
全部
60,400
临床试验
36,150
药物
7,627
机构
1,389
资讯
15,234
上个月
Tasrif Pharmaceutical Secures Second U.S. Patent for CD155-Targeting Antibodies as Anti-TIGIT Field Contracts
去年
Formation Bio Licenses First-in-Class Anti-CD226 Monoclonal Antibody for Autoimmune Diseases
去年
Cell Source Unveils Breakthrough in Off-the-Shelf CAR-T Cell Therapy at ASH Meeting
3个月前
TIGIT Emerges as a Breakthrough Second-Generation Immune Checkpoint Target to Overcome Cancer Immunotherapy Resistance
3个月前
Semaglutide, Omega-3s, and Diet Shift Next-Generation Epigenetic Aging Clocks in Human Studies
2年前
Gilead's Lenacapavir Shows Promise in HIV Prevention, While GLP-1s Studied for Type 1 Diabetes
去年
GLP-1 Drug Use Surges Among Type 1 Diabetes Patients Despite Safety Concerns
去年
GLP-1 Receptor Agonists Prescriptions Rise for Off-Label Use in Type 1 Diabetes
去年
Arbor Biotechnologies' ABO-101 Receives FDA Clearance for Phase 1/2 Trial in Primary Hyperoxaluria Type 1
去年
SAB-142 Shows Promise in Phase 1 Trial for Type 1 Diabetes
第 1 页,共 1524 页
上一页
下一页